Matthew K. Fust - Insider Trading & Ownership

Entity
Individual
Location
C/O Ultragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato, CA
Summary
The estimated net worth of Matthew K. Fust is at least $2.48M dollars as of October 18, 2024. Matthew K. Fust is the Director of Crinetics Pharmaceuticals, Inc. and owns shares of Crinetics Pharmaceuticals, Inc. (CRNX) stock worth about $1.04M. Matthew K. Fust is the Director of Ultragenyx Pharmaceutical Inc. and owns shares of Ultragenyx Pharmaceutical Inc. (RARE) stock worth about $909K. Matthew K. Fust is the Director of Neumora Therapeutics, Inc. and owns shares of Neumora Therapeutics, Inc. (NMRA) stock worth about $342K. Matthew K. Fust is the Director of Atara Biotherapeutics, Inc. and owns shares of Atara Biotherapeutics, Inc. (ATRA) stock worth about $186K.
All Insider Reports
All Insider Reports

Ownership of Matthew K. Fust

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
CRNX Crinetics Pharmaceuticals, Inc. Director $1.04M -$2.65M -71.8% Jun 7, 2024
RARE Ultragenyx Pharmaceutical Inc. Director $909K -$620K -40.6% Jun 18, 2024
NMRA Neumora Therapeutics, Inc. Director $342K -$371K -52% Oct 17, 2024
ATRA Atara Biotherapeutics, Inc. Director $186K Mar 31, 2024

Insider Transactions Reported by Matthew K. Fust:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.